Tonya Sanchez
Tanzania
Review Article
Elimination of Cancer Health Disparities through the Acceleration of HPV Vaccines and Vaccinations: A Simplified Version of the President’s Cancer Panel Report on HPV Vaccinations
Author(s): Eva McGhee, Hill Harper, Adaku Ume, Melanie Baker, Cheick Diarra, John Uyanne, Sebhat Afework, Keosha Partlow, Lucy Tran, Judith Okoro, Anh Doan, Karen Tate, Mechelle Rouse, Meidrah Tyler, Kamilah Evans, Tonya Sanchez, Ishmum Hasan, Enijah Smith-Joe, Jasmine Maniti, Liliana Zarate, Camille King, Antoinette Alugbue, Chiamaka Opara, Bileko Wissa, Joanne Maniti and Roland PattilloEva McGhee, Hill Harper, Adaku Ume, Melanie Baker, Cheick Diarra, John Uyanne, Sebhat Afework, Keosha Partlow, Lucy Tran, Judith Okoro, Anh Doan, Karen Tate, Mechelle Rouse, Meidrah Tyler, Kamilah Evans, Tonya Sanchez, Ishmum Hasan, Enijah Smith-Joe, Jasmine Maniti, Liliana Zarate, Camille King, Antoinette Alugbue, Chiamaka Opara, Bileko Wissa, Joanne Maniti and Roland Pattillo
The human papillomavirus (HPV) is a major public health concern affecting both females and males. HPV is associated with cervical, anal, head and neck cancers. About 99% of all cervical cancers are related to HPV. HPV vaccines, Gardasil, Cervarix, and Gardasil 9 are used in the primary prevention of HPV related cancers. Gardasil and Gardasil 9 are available for use in both females and males ages 9 to 26, while Cervarix is available for females ages 9 to 25. Gardasil 9 was approved by the FDA for prevention against additional HPV types. Despite the availability of this preventative measure against cervical cancer, the rate of HPV vaccination in the United States remains lower than that of other industrialized nations. The purpose of this study is to elucidate mechanisms to help increase the HPV vaccination rate by using education as a tool; by simplifying the president report so that l.. View More»
DOI:
10.4172/2157-7560.1000361